hotspot -WSS

hotspot

author：comprehensive 2025-09-27 15:59:15 - browse：259

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

WSS

Alabama IVF ruling threatens families facing fatal genetic disease

Ford recalls 870K F

STAT readers on older presidents, polypills, Medicare, and more

The mammogram wars are not over

Why palliative psychiatry is worth discussing

Medicare inequities exacerbate Puerto Rico’s health disparities

focus

hotspot

focus

Bright Health sells Medicare Advantage business to Molina

Obesity drugs seen as possible treatment for liver disease MASH

New air purifier tech could be key to improving indoor air quality

A new nitrogen execution bill also undermines medical licensing

DIEP, the 'gold standard' of breast reconstruction, is under threat

Community Health Systems hospitals under DOJ investigation

Medical leaders decry Supreme Court decision on affirmative action

Hospitals, health systems can help patients avoid medical debt

23andMe had bad news about my health. I wish a person had delivered it

Stoke drug shows lower activity against childhood epilepsy

focus

Will biotech layoffs continue through 2023?

Stoke drug shows lower activity against childhood epilepsy

Interest rates are at a 22

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

CDC: Cases of alpha

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

knowledge

explore

Wikipedia

leisure time